Amplify Transformational Data Sharing ETF vs BioNano Genomics Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.55, while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BLOK | BNGO | |
|---|---|---|
52-Week High | $74.10 | $4.92 |
52-Week Low | $47.36 | $1.06 |
Market Cap | — | $13.66M |
Sector | — | Health |
Enterprise Value | — | $16.26M |
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with bearish technical signals from moving averages. The ETF shows mixed sentiment with institutional position adjustments and positive coverage on AI infrastructure exposure. Key support sits at $58-59 while resistance levels begin at $61.
Outlook remains cautious given bearish technical indicators and institutional selling pressure. The fund's diversified blockchain economy exposure offers growth potential but faces volatility risks from sector concentration and regulatory uncertainty.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Trailing returns across standard periods
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →